PROCEPT BioRobotics Stock (NASDAQ:PRCT)
Previous Close
$72.85
52W Range
$45.20 - $103.81
50D Avg
$86.28
200D Avg
$73.59
Market Cap
$3.97B
Avg Vol (3M)
$765.20K
Beta
1.00
Div Yield
-
PRCT Company Profile
PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally-invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). The company also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. As of December 31, 2021, it had an install base of 130 AquaBeam Robotic Systems worldwide comprising 78 in the United States. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in Redwood City, California.
PRCT Performance
Peer Comparison
| Ticker | Company |
|---|---|
| TMCI | Treace Medical Concepts, Inc. |
| ESTA | Establishment Labs Holdings Inc. |
| AXGN | AxoGen, Inc. |
| LUNG | Pulmonx Corporation |
| KIDS | OrthoPediatrics Corp. |
| CNMD | CONMED Corporation |
| FNA | Paragon 28, Inc. |
| SGHT | Sight Sciences, Inc. |
| SIBN | SI-BONE, Inc. |
| RXST | RxSight, Inc. |
| NPCE | NeuroPace, Inc. |
| LIVN | LivaNova PLC |
| SRDX | Surmodics, Inc. |
| ITGR | Integer Holdings Corporation |
| OFIX | Orthofix Medical Inc. |